UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 473

Sortiert nach

How I treat brain metastases of melanoma

ESMO open, 2022-12, Vol.7 (6), p.100598-100598, Article 100598

2022

Volltextzugriff (PDF)

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States

ESMO open, 2021-10, Vol.6 (5), p.100252-100252, Article 100252

2021

Volltextzugriff (PDF)

A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

Annals of oncology, 2018-10, Vol.29, p.viii400-viii400

2018

Volltextzugriff (PDF)

Interleukin-2 in the treatment of renal cancer

Seminars in oncology, 2000-04, Vol.27 (2), p.194

Margolin, K A

2000

Volltextzugriff (PDF)

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors

Annals of oncology, 2015-12, Vol.26 (12), p.2507-2508

2015

Volltextzugriff (PDF)

Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’: [ESMO Open Volume 6, Issue 5, October 2021, 100252]

ESMO open, 2021-12, Vol.6 (6), p.100286-100286, Article 100286

2021

Volltextzugriff (PDF)

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

European journal of cancer (1990), 2015-09, Vol.51, p.S720-S721

2015

Volltextzugriff (PDF)

Health Care Costs in Patients Treated with Ipilimumab for Advanced Melanoma Results of a Retrospective Chart Review

Value in health, 2014-11, Vol.17 (7), p.A615-A615

2014

Volltextzugriff (PDF)

High Dose Chemotherapy and Stem Cell Support in the Treatment of Germ Cell Cancer

The Journal of urology, 2003-04, Vol.169 (4), p.1229-1233

MARGOLIN, KIM

2003

Volltextzugriff (PDF)

Synergistic Effect of TVEC and Radiotherapy in the Treatment of Advanced Melanoma

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e342-e342

2023

Volltextzugriff (PDF)

9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases

European journal of cancer (1990), 2011, Vol.47, p.S654-S654

2011

Volltextzugriff (PDF)

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

Journal of clinical oncology, 2010-11, Vol.28 (33), p.4906-4911

2010

Volltextzugriff (PDF)

LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

Annals of oncology, 2023-06, Vol.34, p.S178-S179

2023

Volltextzugriff (PDF)

LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

Annals of oncology, 2022-06, Vol.33, p.S376

2022

Volltextzugriff (PDF)

An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder

Annals of oncology, 2017-09, Vol.28, p.v425-v425

2017

Volltextzugriff (PDF)

An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder

Annals of oncology, 2017-09, Vol.28, p.v425-v426

2017

Volltextzugriff (PDF)

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

Annals of oncology, 2016-10, Vol.27, p.vi379-vi379

2016

Volltextzugriff (PDF)

Healthcare Resource Utilization (Hcru) in Patients Receiving Ipilimumab for Advanced Melanoma: Impact of Survival and Eastern Cooperative Oncology Group (Ecog) Status

Annals of oncology, 2014-09, Vol.25, p.iv381

2014

Volltextzugriff (PDF)

Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002

Annals of oncology, 2017-09, Vol.28, p.v434-v434

2017

Volltextzugriff (PDF)

Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’: ESMO Open Volume 6, Issue 5, October 2021, 100252

ESMO open, 2021-10, Vol.6 (6)

2021

Volltextzugriff (PDF)

9306 Phase II multi-institution trial of ipilimumab for patients with melanoma and brain metastasis

European journal of cancer supplements, 2009, Vol.7 (2), p.578-578

2009

Volltextzugriff (PDF)

Efficacité et tolérance de l’association du nivolumab (NIVO) et de l’ipilimumab (IPI) chez des patients atteints d’un mélanome et présentant des métastases cérébrales symptomatiques

Annales de dermatologie et de vénéréologie, 2019-12, Vol.146 (12), p.A333-A334

2019

Volltextzugriff (PDF)

PCN9 - Health Care Costs in Patients Treated with Ipilimumab for Advanced Melanoma Results of a Retrospective Chart Review

Value in health, 2014-11, Vol.17 (7), p.A615-A615

2014

Volltextzugriff (PDF)

The treatment of brain metastases from malignant melanoma

Seminars in oncology, 2002-10, Vol.29 (5), p.518-524

2002

Volltextzugriff (PDF)

Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer

Blood, 1997-03, Vol.89 (5), p.1521-1528

1997

Volltextzugriff (PDF)

1 – 25 von 473

Suche als RSS-Feed

Aktive Filter

ThemaFemale

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(416)
Mit Volltextzugriff
(404)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

How I treat brain metastases of melanoma

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States

A personal neoantigen vaccine, NEO-PV-01, with anti-PD1 induces broad de novo anti-tumor immunity in patients with metastatic melanoma, NSCLC, and bladder cancer

Interleukin-2 in the treatment of renal cancer

Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors

Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’: [ESMO Open Volume 6, Issue 5, October 2021, 100252]

22LBA Activity of PD-1 blockade with pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma

Health Care Costs in Patients Treated with Ipilimumab for Advanced Melanoma Results of a Retrospective Chart Review

High Dose Chemotherapy and Stem Cell Support in the Treatment of Germ Cell Cancer

Synergistic Effect of TVEC and Radiotherapy in the Treatment of Advanced Melanoma

9306 ORAL Safety and Efficacy of Ipilimumab-treated Patients With Melanoma and Brain Metastases

Prognostic Factors in Patients With Metastatic Germ Cell Tumors Who Experienced Treatment Failure With Cisplatin-Based First-Line Chemotherapy

LBA-4 Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

LBA O-9 Botensilimab, a novel innate/adaptive immune activator, plus balstilimab (anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer

An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder

An open-label, Phase IB study of NEO-PV-01 + Adjuvant with Nivolumab in Patients with Melanoma, Non-Small Cell Lung Carcinoma, or Transitional Cell Carcinoma of the Bladder

Final overall survival for KEYNOTE-002: pembrolizumab (pembro) versus investigator-choice chemotherapy (chemo) for ipilimumab (ipi)-refractory melanoma

Healthcare Resource Utilization (Hcru) in Patients Receiving Ipilimumab for Advanced Melanoma: Impact of Survival and Eastern Cooperative Oncology Group (Ecog) Status

Analysis of response and survival in patients (pts) with ipilimumab (ipi)-refractory melanoma treated with pembrolizumab (pembro) in KEYNOTE-002

Corrigendum to ‘Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States’: ESMO Open Volume 6, Issue 5, October 2021, 100252

9306 Phase II multi-institution trial of ipilimumab for patients with melanoma and brain metastasis

Efficacité et tolérance de l’association du nivolumab (NIVO) et de l’ipilimumab (IPI) chez des patients atteints d’un mélanome et présentant des métastases cérébrales symptomatiques

PCN9 - Health Care Costs in Patients Treated with Ipilimumab for Advanced Melanoma Results of a Retrospective Chart Review

The treatment of brain metastases from malignant melanoma

Effect of CD34+ Selection and Various Schedules of Stem Cell Reinfusion and Granulocyte Colony-Stimulating Factor Priming on Hematopoietic Recovery After High-Dose Chemotherapy for Breast Cancer

Aktive Filter

Suchergebnisse filtern